Centessa Pharmaceuticals (CNTA) Competitors $13.70 +0.47 (+3.55%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$13.70 0.00 (0.00%) As of 04:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTA vs. ROIV, SRPT, RVMD, LNTH, TGTX, LEGN, BBIO, AXSM, TLX, and BPMCShould you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Roivant Sciences (ROIV), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), Lantheus (LNTH), TG Therapeutics (TGTX), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Centessa Pharmaceuticals vs. Roivant Sciences Sarepta Therapeutics Revolution Medicines Lantheus TG Therapeutics Legend Biotech BridgeBio Pharma Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Centessa Pharmaceuticals (NASDAQ:CNTA) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Does the media prefer CNTA or ROIV? In the previous week, Centessa Pharmaceuticals had 11 more articles in the media than Roivant Sciences. MarketBeat recorded 19 mentions for Centessa Pharmaceuticals and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.13 beat Centessa Pharmaceuticals' score of 0.53 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in CNTA or ROIV? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 11.6% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 7.9% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is CNTA or ROIV more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -52.13% -38.01% Roivant Sciences -119.54%-14.05%-12.81% Do analysts rate CNTA or ROIV? Centessa Pharmaceuticals presently has a consensus target price of $27.71, suggesting a potential upside of 102.29%. Roivant Sciences has a consensus target price of $17.50, suggesting a potential upside of 73.61%. Given Centessa Pharmaceuticals' higher probable upside, research analysts clearly believe Centessa Pharmaceuticals is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better earnings and valuation, CNTA or ROIV? Roivant Sciences has higher revenue and earnings than Centessa Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M263.57-$151.09M-$1.99-6.88Roivant Sciences$122.59M58.67$4.35B-$0.15-67.20 Which has more risk and volatility, CNTA or ROIV? Centessa Pharmaceuticals has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Does the MarketBeat Community believe in CNTA or ROIV? Roivant Sciences received 20 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 78.26% of users gave Roivant Sciences an outperform vote while only 60.71% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCentessa PharmaceuticalsOutperform Votes3460.71% Underperform Votes2239.29% Roivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% SummaryCentessa Pharmaceuticals and Roivant Sciences tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTA vs. The Competition Export to ExcelMetricCentessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81B$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-8.957.1123.1318.81Price / Sales263.57207.54368.2888.86Price / CashN/A65.6738.1634.64Price / Book5.666.146.704.18Net Income-$151.09M$142.11M$3.20B$247.10M7 Day Performance-5.58%-6.00%-3.92%-2.74%1 Month Performance-8.91%-6.96%1.69%-3.92%1 Year Performance26.62%-12.14%8.44%-0.12% Centessa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTACentessa Pharmaceuticals2.9361 of 5 stars$13.70+3.6%$27.71+102.3%+20.9%$1.81B$6.85M-8.95200Analyst ForecastAnalyst RevisionROIVRoivant Sciences2.4231 of 5 stars$10.83+0.4%$18.08+67.0%-7.7%$7.73B$122.59M-72.20860SRPTSarepta Therapeutics4.8474 of 5 stars$76.33+3.0%$167.41+119.3%-50.8%$7.41B$1.90B61.061,314Quiet Period ExpirationNews CoverageRVMDRevolution Medicines4.2054 of 5 stars$39.34+3.2%$66.31+68.6%+11.9%$7.31B$742,000.00-10.96250Analyst ForecastLNTHLantheus4.3886 of 5 stars$99.44+1.8%$129.43+30.2%+65.5%$6.81B$1.53B16.55700Positive NewsTGTXTG Therapeutics3.0584 of 5 stars$42.61-0.9%$40.67-4.6%+175.8%$6.69B$329.00M-426.06290Positive NewsLEGNLegend Biotech2.5491 of 5 stars$36.33-1.7%$79.00+117.5%-41.1%$6.67B$627.24M-38.241,800Short Interest ↓Positive NewsBBIOBridgeBio Pharma4.6645 of 5 stars$37.22+7.0%$52.90+42.1%+20.2%$6.61B$221.90M-13.06400Analyst ForecastOptions VolumeHigh Trading VolumeAXSMAxsome Therapeutics4.7484 of 5 stars$129.17+1.9%$167.36+29.6%+47.2%$6.30B$385.69M-21.56380Analyst ForecastShort Interest ↓News CoverageTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.24+2.5%$22.00+20.6%N/A$6.14B$783.21M0.00N/AGap UpBPMCBlueprint Medicines2.8259 of 5 stars$95.27+7.4%$124.95+31.2%-1.7%$6.09B$508.82M-88.21640Positive News Remove Ads Related Companies and Tools Related Companies ROIV Alternatives SRPT Alternatives RVMD Alternatives LNTH Alternatives TGTX Alternatives LEGN Alternatives BBIO Alternatives AXSM Alternatives TLX Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
